Gan and Lee Pharmaceuticals (SHSE:603087) Short-Term Debt: ¥0 Mil (As of Jun. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Gan and Lee Pharmaceuticals SHSE:603087

90 GF Score

Price ¥66.34

GF Value ¥73.00

Valuation Fairly Valued

5 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Gan and Lee Pharmaceuticals Short-Term Debt?

Gan and Lee Pharmaceuticals SHSE:603087 -2.27% 90 Short-Term Debt is ¥0 Mil as of Jun. 2026. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review.

Gan and Lee Pharmaceuticals's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥0 Mil.

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Gan and Lee Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Gan and Lee Pharmaceuticals Short-Term Debt Related Terms

Gan and Lee Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Gan and Lee Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan and Lee Pharmaceuticals Short-Term Debt Chart

Gan and Lee Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Short-Term Debt

Get a 7-Day Free Trial

0.00

Gan and Lee Pharmaceuticals Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
Short-Term Debt	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

90GF Score

Gan and Lee Pharmaceuticals SHSE:603087

Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Frequently Asked Questions Learn more about Short-Term Debt →

What does a Short-Term Debt of ¥0 Mil mean?

Gan and Lee Pharmaceuticals (SHSE:603087) has a Short-Term Debt of ¥0 Mil as of Jun. 2026.

Is Gan and Lee Pharmaceuticals' Short-Term Debt too high?

Gan and Lee Pharmaceuticals' current Short-Term Debt is ¥0 Mil. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Gan and Lee Pharmaceuticals' Short-Term Debt compare to ISRG and BDX?

Gan and Lee Pharmaceuticals' Short-Term Debt of ¥0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Short-Term Debt for a Medical Devices & Instruments company?

A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Short-Term Debt mean?

A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Gan and Lee Pharmaceuticals's current Short-Term Debt is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Gan and Lee Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Short-Term Debt is ¥0 Mil. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Short-Term Debt calculated?

Short-Term Debt is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Short-Term Debt is ¥0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?

Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued. The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00. GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.

Key valuation signals for SHSE:603087:

Short-Term Debt: ¥0 Mil
GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →